Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study
Diabetes Care · 2025
DOI: 10.2337/dc24-1652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2025. Verfasst von Anna Shin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Collaboration Center, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Nephrolithiasis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Seoul National University Bundang Hospital, Korea Health Industry Development Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE We aim to compare the risk of nephrolithiasis among type 2 diabetes patients who initiated sodium–glucose cotransporter 2 inhibitors (SGLT2is) versus dipeptidyl peptidase 4 inhibitors (DPP4is), individually within stone never- and ever-formers. RESEARCH DESIGN AND METHODS Using the 2010–2021 Korea National Health Insurance Service database, we conducted a population-based cohort study, comparing initiators of SGLT2is versus DPP4is. The primary outcome was incident nephrolithiasis. Osteoarthritis encounters served as a negative control outcome. After 1:1 propensity score (PS) matching in stone never- and ever-formers, pooled and individual hazard ratios (HRs), incidence rate difference (IRD), and 95% CIs were reported. Subgroup analyses by sex, age, thiazide co-use, and baseline cardiovascular risk were done. RESULTS The 17,006 PS-matched pairs of SGLT2i and DPP4i initiators were pooled from stone never-formers (105,378 pairs) and ever-formers (11,628 pairs). Over a mean of 654 days, the risk of nephrolithiasis was lower in SGLT2i initiators than in DPP4i initiators: 0.65 vs. 1.12 events per 100 person-years, HR 0.54 (95% CI, 0.50–0.57), IRD −0.46 (95% CI, −0.21 to −0.52). Among never-formers, the HR was 0.43 (95% CI, 0.39–0.48) and IRD was −0.32 (95% CI, −0.27 to −0.36). Among ever-formers, the HR was 0.64 (95% CI, 0.59–0.69) and IRD was −2.26 (95% CI, −1.77 to −2.76). Near-null associations were found for osteoarthritis encounters. Results were consistent across subgroups. CONCLUSIONS We found a lower risk of nephrolithiasis associated with SGLT2is versus DPP4is in stone never- and ever-formers. Despite a greater relative risk reduction in the former, the absolute risk reduction was greater in the latter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Research Collaboration Center, Seoul National University Bundang Hospital, Seongnam, Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
ORCID-Profile: Ju-Young Shin, Eun Ha Kang
Förderung
- Seoul National University Bundang Hospital
- Korea Health Industry Development Institute
Zitieren
APA
Shin, A., Shin, J. Y., & Kang, E. H. (2025). Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study. Diabetes Care. https://doi.org/10.2337/dc24-1652
Vancouver
Shin A, Shin JY, Kang EH. Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study. Diabetes Care. 2025. doi:10.2337/dc24-1652
BibTeX
@article{Shin2025,
author = {Shin, Anna and Shin, Ju-Young and Kang, Eun Ha},
title = {Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc24-1652}
}
EUVIMED